Avian influenza nanoparticle immunogenic compositions
Patent Information
- Application Number
- PCT/US2025/018378
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-11-13
- Filing Date
- 2025-03-04
- Publication Date
- 2025-10-02
AI Technical Summary
There is a need for the development of safe, effective, and ideally single-dose vaccines against highly pathogenic avian influenza (HPAI) A(H5N1) viruses, which have a high fatality rate and pose a significant public health risk due to their potential for human-to-human transmissibility and pandemic potential.
The development of influenza vaccine nanoparticles composed of recombinant avian influenza hemagglutinin (HA) glycoprotein from subtype A(H5N1) combined with a Matrix-M adjuvant, forming nanoparticles through a detergent exchange process, which enhances immune response when administered intramuscularly or intranasally.
The vaccine nanoparticles induce robust innate and adaptive immune responses, including seroconverting antibodies and cell-mediated immunity, providing effective protection against A(H5N1) infections.